229 related articles for article (PubMed ID: 19889936)
1. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Sanchez-Perez LA; Choi BD; Archer GE; Cui X; Flores C; Johnson LA; Schmittling RJ; Snyder D; Herndon JE; Bigner DD; Mitchell DA; Sampson JH
PLoS One; 2013; 8(3):e59082. PubMed ID: 23527092
[TBL] [Abstract][Full Text] [Related]
3. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
Park SD; Kim CH; Kim CK; Park JA; Sohn HJ; Hong YK; Kim TG
Vaccine; 2007 Apr; 25(17):3485-91. PubMed ID: 17275143
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Dai B; Qi N; Li J; Zhang G
Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Kim CH; Woo SJ; Park JS; Kim HS; Park MY; Park SD; Hong YK; Kim TG
Immunology; 2007 Dec; 122(4):615-22. PubMed ID: 17645496
[TBL] [Abstract][Full Text] [Related]
6. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
7. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
[TBL] [Abstract][Full Text] [Related]
9. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
10. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Batich KA; Reap EA; Archer GE; Sanchez-Perez L; Nair SK; Schmittling RJ; Norberg P; Xie W; Herndon JE; Healy P; McLendon RE; Friedman AH; Friedman HS; Bigner D; Vlahovic G; Mitchell DA; Sampson JH
Clin Cancer Res; 2017 Apr; 23(8):1898-1909. PubMed ID: 28411277
[No Abstract] [Full Text] [Related]
11. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
Zhu X; Lu C; Xiao B; Qiao J; Sun Y
J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.
Kim CH; Hong MJ; Park SD; Kim CK; Park MY; Sohn HJ; Cho HI; Kim TG; Hong YK
Cancer Immunol Immunother; 2006 Nov; 55(11):1309-19. PubMed ID: 16463038
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Akasaki Y; Kikuchi T; Homma S; Koido S; Ohkusa T; Tasaki T; Hayashi K; Komita H; Watanabe N; Suzuki Y; Yamamoto Y; Mori R; Arai T; Tanaka T; Joki T; Yanagisawa T; Murayama Y
Cancer Immunol Immunother; 2016 Dec; 65(12):1499-1509. PubMed ID: 27688162
[TBL] [Abstract][Full Text] [Related]
15. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Mitchell DA; Cui X; Schmittling RJ; Sanchez-Perez L; Snyder DJ; Congdon KL; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Blood; 2011 Sep; 118(11):3003-12. PubMed ID: 21768296
[TBL] [Abstract][Full Text] [Related]
17. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.
Yamanaka R; Zullo SA; Ramsey J; Yajima N; Tsuchiya N; Tanaka R; Blaese M; Xanthopoulos KG
J Neurosurg; 2002 Sep; 97(3):611-8. PubMed ID: 12296646
[TBL] [Abstract][Full Text] [Related]
18. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.
Yamanaka R; Zullo SA; Tanaka R; Blaese M; Xanthopoulos KG
J Neurosurg; 2001 Mar; 94(3):474-81. PubMed ID: 11235953
[TBL] [Abstract][Full Text] [Related]
20. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
